SCHEMBL515354

SCHEMBL515354

O=C(CCCC(O)c1ccc(F)cc1)N1CCOC1=O

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 13/20 0.67
FAAH O00519 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL541594 1.00 NAAA (0.67) NAAAFAAH
SCHEMBL10045399 0.84 NAAA (0.57) NAAAFAAH
SCHEMBL524458 0.80 KDM4E (0.56)
SCHEMBL523656 0.80 KDM4E (0.56)
SCHEMBL524333 0.80 KDM4E (0.56)
SCHEMBL13345791 0.80 NAAA (0.68) NAAAFAAH
SCHEMBL14206854 0.80 NAAA (1.00) NAAAFAAH
SCHEMBL19490715 0.77 NAAA (0.54) NAAA
SCHEMBL14642159 0.77 NAAA (0.40) NAAA
SCHEMBL19825342 0.76 NAAA (0.80) NAAAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414339-B1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-[5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LTD (IN) 2013-01-16 EP claimed
US-8178665-B2 Process for the production of ezetimibe and intermediates used in this process RICHTER GEDEON NYRT. (HU) 2012-05-15 US disclosed
EP-2414339-A1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-Ý5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL¨-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER Lupin Ltd. (IN) 2012-02-08 EP disclosed
US-20120028340-A1 KINETIC RESOLUTION OF (4S) -- 4- PHENYL -- 3- [(5RS)-5-(4-FLUROPHENYL)-5- HYDROXYPENTANOYL] --1,3-OXAZOLIDIN-2-ONE TO THE (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LIMITED (IN) 2012-02-02 US disclosed
EP-1963260-B1 PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS RICHTER GEDEON NYRT (HU) 2010-11-03 EP disclosed
US-20090216009-A1 PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS RICHTER GEDEON NYRT. (HU) 2009-08-27 US disclosed
EP-1963260-A1 PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES Richter Gedeon NYRT (HU) 2008-09-03 EP disclosed
WO-2007072088-A1 PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES RICHTER GEDEON NYRT. (HU) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090216009-A1 PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS APOB, HMGCR, PCSK9 NAAA 1839/4885FAAH 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.